Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Dec / Transforming Tumor Testing
Oncology Omics Oncology Technology and innovation

Transforming Tumor Testing

Ribosomal RNA modifications as biomarkers provide insights into epitranscriptomic fingerprinting

By Jessica Allerton 12/20/2024 News 1 min read

Share

A recent study published in Molecular Cell highlights the potential of ribosomal RNA (rRNA) modifications as powerful diagnostic tools. The researchers demonstrated that epitranscriptomic fingerprinting – a method based on analyzing rRNA modification patterns – can accurately identify tissue origins and distinguish tumors from normal samples. Using direct RNA sequencing (DRS), they discovered dynamic rRNA modification patterns across tissues, developmental stages, and cancer states.

Original Image: Adobestock.com

DRS technology enables direct sequencing of native RNA molecules while preserving modification and sequence integrity. Using this technique, the researchers were able to classify tumor and normal samples with high accuracy using only 250 sequencing reads per sample. They also uncovered novel rRNA modification sites, including previously unannotated pseudouridylation residues, and mapped cancer-specific patterns. In lung cancer samples, differentially modified sites provided clear separation between tumor and normal tissues.

By analyzing over 220 rRNA modifications, including ribose methylation and pseudouridylation, the team demonstrated how these signatures are enriched in tumors and vary across tissue types. Machine learning further enhanced the predictive power of these modifications for diagnosing malignancies and determining tissue origins.

This method offers a significant advantage over traditional diagnostics. Unlike mRNA-focused techniques, which may lack stability or specificity, rRNA modifications provide distinct, robust signatures for classification. The approach requires minimal sampling, making it highly feasible for clinical applications. Beyond cancer, this method holds promise for identifying tissue-specific changes linked to normal development and disease progression.

Epitranscriptomic fingerprinting represents a major shift in diagnostics, the study reports. Its ability to leverage rRNA modifications for precise, non-invasive cancer detection and tissue identification paves the way for new diagnostic and therapeutic strategies. Future research could expand this method to other diseases and advance its use in clinical practice.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.